<DOC>
	<DOCNO>NCT01358903</DOCNO>
	<brief_summary>This open-label 2-arm study ass pharmacokinetics , pharmacodynamics , safety efficacy RO5429083 patient metastatic and/or locally advance CD44-expressing malignant solid tumor . In Part A , cohorts patient receive RO5429083 intravenously escalate dos . In Part B , patient receive 89Zr-labelled RO5429083 Cycles 1 and/or 2 , follow RO5429083 . For patient option continue treatment RO5429083 disease progression unacceptable toxicity occur .</brief_summary>
	<brief_title>A Study RO5429083 Patients With Metastatic and/or Locally Advanced , CD44-Expressing , Malignant Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Adult patient , &gt; /= 18 year age Metastatic and/or locally advance malignant CD44expressing solid tumor Patients disease progression standard therapy , tumor curable standard therapy Life expectancy 12 week Concurrent therapy investigational drug Known suspect CNS metastasis include leptomeningeal metastasis Active bleeding , bleed diathesis history coagulation disorder Uncontrolled diabetes mellitus Active uncontrolled infection Patients HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>